Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 1549063, 6 pages
http://dx.doi.org/10.1155/2016/1549063
Research Article

Serum Galectin and Renal Dysfunction in ST-Segment Elevation Myocardial Infarction

1Federal State Budgetary Institution “Research Institute for Complex Issues of Cardiovascular Diseases”, 6 Sosnovy Boulevard, Kemerovo 650002, Russia
2Federal State Budget Educational Institution of Higher Professional Education “Kemerovo State Medical Academy of the Ministry of Health of the Russian Federation”, 22a Voroshilov Street, Kemerovo 650029, Russia

Received 20 October 2015; Revised 10 January 2016; Accepted 19 January 2016

Academic Editor: Mariann Harangi

Copyright © 2016 Victoria Karetnikova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Solomenchyk, K. Semegen-Bodak, N. Slaba, G. Tshngryan, and O. Klymkovich, “Proaterogenic metabolic disorders in patients with chronic kidney disease nondiabetic origin: possibility of statin therapy,” Kardiologiya, vol. 54, no. 6, pp. 40–43, 2014. View at Google Scholar · View at Scopus
  2. O. L. Barbarash, M. V. Zykov, I. S. Bykova, V. V. Kashtalap, V. N. Karetnikova, and L. S. Barbarash, “Role of renal dysfunction and multifocal atherosclerosis in assessment of prognosis of patients presenting with ST-elevation acute coronary syndrome,” Kardiologiya, vol. 53, no. 9, pp. 26–32, 2013. View at Google Scholar · View at Scopus
  3. D. J. Lok, P. Van Der Meer, P. W. de la Porte et al., “Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure,” Clinical Research in Cardiology, vol. 99, no. 5, pp. 323–328, 2010. View at Publisher · View at Google Scholar
  4. R. V. Shah, A. A. Chen-Tournoux, M. H. Picard, R. R. J. van Kimmenade, and J. L. Januzzi, “Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure,” European Journal of Heart Failure, vol. 12, no. 8, pp. 826–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. V. V. Glinsky and A. Raz, “Modified citrus pectin anti-metastatic properties: one bullet, multiple targets,” Carbohydrate Research, vol. 344, no. 14, pp. 1788–1791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kolatsi-Joannou, K. L. Price, P. J. Winyard, and D. A. Long, “Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury,” PLoS ONE, vol. 6, no. 4, Article ID e18683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Levey, L. A. Stevens, C. H. Schmid et al., “A new equation to estimate glomerular filtration rate,” Annals of Internal Medicine, vol. 150, no. 9, pp. 604–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Taglieri, W. Koenig, and J. C. Kaski, “Cystatin C and cardiovascular risk,” Clinical Chemistry, vol. 55, no. 11, pp. 1932–1943, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Tangri, L. A. Stevens, C. H. Schmid et al., “Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate,” Kidney International, vol. 79, no. 4, pp. 471–477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. R. V. Shah, A. A. Chen-Tournoux, M. H. Picard, R. R. J. Van Kimmenade, and J. L. Januzzi, “Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure,” European Journal of Heart Failure, vol. 12, no. 8, pp. 826–832, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. J. E. Ho, C. Liu, A. Lyass et al., “Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community,” Journal of the American College of Cardiology, vol. 60, no. 14, pp. 1249–1256, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. R. A. de Boer, D. J. van Veldhuisen, R. T. Gansevoort et al., “The fibrosis marker galectin-3 and outcome in the general population,” Journal of Internal Medicine, vol. 272, no. 1, pp. 55–64, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Yu, W. P. T. Ruifrok, M. Meissner et al., “Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis,” Circulation: Heart Failure, vol. 6, no. 1, pp. 107–117, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Nishi, H. Sano, T. Kawashima et al., “Role of galectin-3 in human pulmonary fibrosis,” Allergology International, vol. 56, no. 1, pp. 57–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al., “Galectin-3 regulates myofibroblast activation and hepatic fibrosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5060–5065, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. A. de Boer, A. A. Voors, P. Muntendam, W. H. van Gilst, and D. J. van Veldhuisen, “Galectin-3: a novel mediator of heart failure development and progression,” European Journal of Heart Failure, vol. 11, no. 9, pp. 811–817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. J. N. Nativi, W. K. Kremers, T. Hasin et al., “Abstract 11369: galectin-3, a biomarker of poor prognosis in heart failure remains unchanged after heart transplantation,” Circulation, vol. 126, abstract 11369, 2012. View at Google Scholar
  18. R. A. De Boer, C. Wanner, K. Blouin et al., “Galectin-3 and outcomes in patients with end-stage renal disease: data from the german diabetes and dialysis study,” Circulation, vol. 124, abstract 11743, 2011. View at Google Scholar
  19. N. S. Sherwi, K. M. Goode, J. Zhang et al., “Plasma concentrations of galectin-3 in patients with suspected and confirmed heart failure: distribution, associations and prognostic significance,” Circulation, vol. 124, abstract 17018, 2011. View at Google Scholar
  20. W. H. W. Tang, K. Shrestha, Z. Shao et al., “Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival,” The American Journal of Cardiology, vol. 108, no. 3, pp. 385–390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. de Boer, D. J. A. Lok, T. Jaarsma et al., “Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction,” Annals of Medicine, vol. 43, no. 1, pp. 60–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. S. J. Synowski, W. J. Kop, R. H. Christenson et al., “Elevated levels of galectin-3 are associated with higher levels of C-reactive protein, increased disease severity and poorer prognosis in patients with chronic heart failure,” Circulation, vol. 126, abstract 16594, 2012. View at Google Scholar
  23. T. Ahmad, M. Fiuzat, S. Stevens et al., “Abstract 17649: elevated galectin-3 levels and prediction of mode of death in heart failure: insights from the HF-ACTION study,” Circulation, vol. 126, abstract 17649, 2012. View at Google Scholar